Oryzon Genomics SA is primarily active in the biotechnology industry.

Some of the main competitors of Oryzon Genomics SA in the market include other companies in the field of biotechnology and pharmaceuticals. These can include companies like Roche Holding AG, Novartis AG, and Amgen Inc.

Oryzon Genomics SA is a biopharmaceutical company specializing in epigenetics and precision medicine. Founded in 2000, the Spanish-based company emerged from a joint initiative of scientists and researchers from the University of Barcelona and the Spanish National Research Council. Oryzon Genomics focuses on the development of innovative therapies for serious diseases, such as cancer and neurological disorders, by modulating gene expression through epigenetic mechanisms. They employ cutting-edge technologies and have a robust pipeline of investigational drugs under development. Oryzon Genomics aims to bring novel and effective treatment options to patients and contribute to advancing the field of precision medicine.

Oryzon Genomics SA has achieved several significant milestones. The company successfully completed various clinical trials, including Phase II and Phase IIB studies, for its lead investigational drug, vafidemstat. They have also garnered positive results in these trials, demonstrating the drug's potential for the treatment of various neurological and psychiatric disorders. Oryzon Genomics SA has secured several partnerships and collaborations with renowned institutions and pharmaceutical companies to further advance their research and development efforts. They have also received important regulatory designations, such as Orphan Drug Designation from the U.S. FDA, further validating the potential of their innovative therapies.

Oryzon Genomics SA is primarily present in Spain and the United States.

Oryzon Genomics SA represents core values of innovation, integrity, and collaboration. This biopharmaceutical company is committed to advancing precision medicine through cutting-edge research and development. With a focus on epigenetics, Oryzon Genomics SA aims to discover and develop novel therapies for serious diseases such as cancer and neurodegenerative disorders. The company's corporate philosophy revolves around ethically transforming scientific knowledge into tangible solutions for patients worldwide. By fostering partnerships and leveraging its expertise, Oryzon Genomics SA strives to bring about meaningful advancements in the field of personalized medicine.

Analysts currently set an average price target of 7,33 EUR for the Oryzon Genomics stock (median: 5,71 EUR), implying +154,4 % versus the latest price. The consensus is based on 10 analyst ratings.

Oryzon Genomics Analyytikkojen kursstavoitteet 2026

10 analysts currently rate the Oryzon Genomics stock: 9 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Oryzon Genomics to generate revenue of 6,56 M EUR and earnings per share of −0,12 EUR.

Oryzon Genomics Analyytikkojen kursstavoitteet 2026

The Oryzon Genomics share (ORY.MC) is listed on 7 stock exchanges, including: Frankfurt (ORN.F), München (ORN.MU), Düsseldorf (ORN.DU), London (0RDB.L), London (0RDB.L).

Oryzon Genomics SA is a biotechnology company specializing in the development of epigenetic-based therapies for neurodegenerative diseases and cancer. The company is headquartered in Spain and has been listed on the Madrid Stock Market since 2015. Oryzon Genomics SA's business model includes several divisions, each with a specific focus to achieve Oryzon's goal of providing innovative therapies for severe and chronic diseases. The main focus is on identifying enzymes involved in epigenetic changes that contribute to the onset of certain diseases. These enzymes are intended to serve as targets for the development of new drugs. The first division of Oryzon Genomics SA is the research and development of drugs. The company has various programs in the field of epigenetics focused on the development of therapeutics for severe diseases. This includes programs for Alzheimer's disease, multiple sclerosis, autism, depression, and various types of cancer. The company focuses on the discovery of new drug classes and works closely with academic institutions and pharmaceutical companies. Another important division of Oryzon is the Mechanism-of-Action (MOA) service. This service helps other pharmaceutical companies understand the mode of action of new drugs. Oryzon offers its service for the analysis of potential drug effectiveness and assists in identifying new therapeutic target structures. This is intended to enable other pharmaceutical companies to develop new drugs more quickly. The company also has a Clinical Development Unit that focuses on the clinical development of new drugs. In this division, data from animal studies and Phase I areas are used to test the efficacy and safety of compounds in clinical trials. The clinical development of drugs is a time-consuming and costly process, but it is also a crucial phase for the approval of a new drug. Another important area of Oryzon Genomics is its service business. Here, the company offers its expertise and experience in epigenetics to assist other pharmaceutical companies and academic institutions in the development of new drugs and diagnostics. The services offered include drug discovery services, analytical and preclinical services, molecular biology and epigenetic services, and assay development services. Finally, the company also offers products such as epigenetic kits and reagents for research. These products are intended to help scientists better understand the mechanisms of epigenetics and develop new therapeutic approaches. In summary, Oryzon Genomics SA's business model is focused on developing innovative therapies for severe and chronic diseases. The company identifies enzymes involved in epigenetic changes and uses them as targets for new drugs. The company has several divisions, including research and development, the MOA service, the Clinical Development Unit, and the service business. Oryzon Genomics SA also offers products such as epigenetic kits and reagents for research and strives to advance the development of new therapeutic approaches in epigenetics.

odotettu liikevaihto Oryzon Genomics on 6,56 M EUR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Oryzon Genomics on −7,50 M EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Oryzon Genomics:n hinta-voitto-suhde (P/E) on tällä hetkellä −24,85. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Oryzon Genomics-osakkeen arvostusta.

Oryzon Genomics:n hinta-myynti-suhde (P/S) on tällä hetkellä 28,43. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Oryzon Genomics-osakkeen arvostuskennuslukuna.

Oryzon Genomics:n Eulpool-laatuscore on 2/10.

Oryzon Genomics:n ISIN on ES0167733015. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Oryzon Genomics:n WKN on A2ACV2. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Oryzon Genomics:n ticker on ORY.MC. Tämä pörssinoteeraus käytetään Oryzon Genomics-osakkeiden kauppaan pörssissä.

Oryzon Genomics maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Oryzon Genomics kuuluu sektoriin 'Terveydenhuolto'.

Oryzon Genomics:n osingot jaetaan valuutassa EUR.